



Complete if Known

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Application Number	10/823,097
Filing Date	04/13/2004
First Named Inventor	BAMDAD, Cynthia
Art Unit	1641
Examiner Name	Pensee T. Do
Attorney Docket Number	M1015.70013US01

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ^o
		Country Code ² Number ⁴ Kind Code ⁵ (if known)				
PD	B1	WO 98/31839 A2	07-23-1998	BAMDAD	whole document	
↓	B2	WO 98/37421 A1	08-27-1998	MAGGIO et al.	whole document	
	B3	WO 99/08695 A1	02-25-1999	GLABE et al.	whole document	
	B4	WO 00/43791 A2	07-27-2000	BAMDAD et al.	whole document	
PD	B5	WO 96/29629 A2	09-26-1996	WHITESIDES et al.	whole document	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/823,097
		Filing Date	04/13/2004
		First Named Inventor	BAMDAD, Cynthia C.
		Art Unit	1641
		Examiner Name	Pensee T. Do
Sheet 1	of 2	Attorney Docket Number	M1015.70013US01

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PD	C1	SIGAL et al., "Self-Assembled Monolayer for the Binding and Study of Histidine-Tagged Proteins by Surface Plasmon Resonance", Analytical Chemistry (1996), 68(3): 490-497	
PD	C2	TERZI et al., "Interaction of Alzheimer Beta-Amyloid Peptide(1-40) with Lipid Membranes", Biochemistry (1997), 36(48): 14845-14852	
PD	C3	LANSBURY, "Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease", Proc. Natl. Acad. Sci. USA (1999), 96: 3342-3344	
PD	C4	JARRETT et al., "The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease", Biochemistry (1993), 32(18): 4693-4697	
PD	C5	HARPER et al., "Observation of metastable Abeta amyloid protofibrils by atomic force microscopy", Chem. Biol. (1997), 4(2): 119-125	
PD	C6	LAIBINIS et al., "Orthogonal Self-Assembled Monolayers: Alkanethiols on Gold and Alkane Carboxylic Acids on Alumina", Science (1989), 245: 845-847	
PD	C7	BAIN et al., "Formation of Monolayers by the Coadsorption of Thiols on Gold: Variation in the Length of the Alkyl Chain", J. Am. Chem. Soc. (1989), 111(18): 7164-7175	
PD	C8	BAIN et al., "Formation of Monolayers by the Coadsorption of Thiols on Gold: Variation in the Head Group, Tail Group, and Solvent", J. Am. Chem. Soc. (1989), 111(18): 7155-7164	
PD	C9	SANNA et al., "Localization of a Passively Transferred Human Recombinant Monoclonal Antibody to Herpes Simplex Virus Glycoprotein D to Infected Nerve Fibers and Sensory Neurons In Vivo", Journal of Virology (1999), 73(10): 8817-8823	
PD	C10	AKERSTROM et al., "Definition of IgG—and albumin-binding regions of streptococcal protein G", J. Biol. Chem. (1987), 262(28): 13388-13391	

Examiner Signature	/Pensee Do/	Date Considered	08/31/2006
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/823,097
		Filing Date	04/13/2004
		First Named Inventor	BAMDAD, Cynthia C.
		Art Unit	1641
		Examiner Name	Pensee T. Do
Sheet 2	of 2	Attorney Docket Number	M1015.70013US01

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PD	C11	FAHNESTOCK et al., "Gene for an Immunoglobulin-Binding Protein from a Group G Streptococcus", Journal of Bacteriology (1986), 167(3): 870-880	
PD	C12	WOLFE et al., "Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ -secretase activity", Nature (1999), 398: 513-517	
PD	C13	LEBLANC et al., "Role of amyloid precursor protein (APP): Study with antisense transfection of human neuroblastoma cells", J. Neurosci. Res. (1992), 31(4): 635-645 (abstract only)	
PD	C14	SELKOE, "The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease", Cell Biology (1998), 8: 447-453	
PD	C15	KNOPS et al., "Cell-type and Amyloid Precursor Protein-type Specific Inhibition of A Release by Bafilomycin A1, a Selective Inhibitor of Vacuolar ATPases", J. Biol. Chem. (1995), 270(6): 2419-2422	
PD	C16	HAASS et al., "The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway", Nat. Med. (1995), 1(12): 1291-1296 (abstract only)	

Examiner Signature	/Pensee Do/	Date Considered	08/31/2006
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.